Telomir Pharmaceuticals, Inc. (TELO)

NASDAQ: TELO · IEX Real-Time Price · USD

3.750

-0.140 (-3.60%)

At close: Jul 19, 2024, 4:00 PM

3.730

-0.020 (-0.53%)

Pre-market: Jul 22, 2024, 7:26 AM EDT

Telomir Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Selling, General & Admin	-	2.37	0.02	0.01
Research & Development	-	1.57	0.83	0.13
Operating Expenses	-	3.94	0.85	0.14
Operating Income	-	-3.94	-0.85	-0.14
Interest Expense / Income	-	1.64	0	0
Other Expense / Income	-	7.49	-	-
Pretax Income	-	-13.07	-0.85	-0.14
Net Income	-	-13.07	-0.85	-0.14
Shares Outstanding (Basic)	28	27	27	-
Shares Outstanding (Diluted)	-	29	27	-
Shares Change	3.50%	8.16%	-	-
EPS (Basic)	-	-0.48	-0.03	-
EPS (Diluted)	-	-0.45	-0.03	-
Free Cash Flow	-	-3.86	-0.47	-0.12
Free Cash Flow Per Share	-	-0.14	-0.02	-
EBITDA	-	-11.43	-0.85	-0.14
EBIT	-	-11.43	-0.85	-0.14

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).